PRF Technologies (PRFX) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PRF Technologies is the larger company by market cap ($3.1 million vs $204,555), about 15.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRFX | SXTC |
|---|---|---|
| Share price | $0.883 | $0.1548 |
| Market cap | $3.09M | $204.56K |
| 1-day change | +2.83% | -54.93% |
| EPS (TTM) | $-4.09 | $-730.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $83,760.00 |
| 52-week low | $0.851 | $0.1494 |
| Distance from 52-week high | -88.89% | -100.00% |
| Average volume | 294.15K | 4.71M |
| Shares outstanding | 3.50M | 1.32M |
| Employees | 6 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRF Technologies is about 15.1 times larger than China SXT Pharmaceuticals by market value ($3.09M vs $204.56K).
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
PRFX vs SXTC FAQ
Which is bigger, PRF Technologies or China SXT Pharmaceuticals?
PRF Technologies (PRFX) is larger, with a market capitalization of $3.09M compared with $204.56K for China SXT Pharmaceuticals (SXTC).
Are PRF Technologies and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.